While vaccine sales dropped, GSK raised its revenue guidance for 2031 with speciality medicines expected to drive that growth ...

Revenue for Arexvy and Abrysvo fell sharply year over year in the fourth quarter due to narrower U.S. guidelines for their use.

Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...

Around the new year, many people set goals for better health. People ages 65 and older can kick off a healthy new year by getting vaccinated for flu, COVID-19 and RSV. These respiratory infections can ...

After a period of unsteady sales for its key COVID-19 products, Pfizer now sees COVID-related revenue volatility as “largely in the past.”  | The company benefited from higher-than-expected sales of ...

During the COVID pandemic, RSV showed a slightly odd pattern: like flu, it basically disappeared in the 2020–2021 season, ...

US-based Inhalon Biopharma is set to launch a trial of its at-home nebulised treatment for respiratory syncytial virus (RSV) ...

From today, February 3, pregnant women in Australia will be eligible for a free RSV vaccine under the National Immunisation ...

By Manuela Bianco Suarez University of Kentucky Healthcare This winter, low temperatures have impacted the state of Kentucky. One of the biggest concerns statewide is the rise in the number of ...

Shionogi’s oral antiviral for respiratory syncytial virus (RSV) has met its primary endpoint in a Phase II study that saw ...

Dupixent continues leading among Sanofi’s portfolio, and it’s poised for up to $20 billion in peak sales. Read my SNY ...